Inovio Shareholders Urged to Join Securities Fraud Lawsuit

Deadline Alert: Investors Who Lost Money on Inovio Stock Encouraged to Contact Law Firm About Potential Claims

Mar. 13, 2026 at 6:23pm

Got story updates? Submit your updates here. ›

Glancy Prongay Wolke & Rotter LLP is reminding investors of the upcoming April 7, 2026 deadline to file as a lead plaintiff in a class action lawsuit against Inovio Pharmaceuticals, Inc. The lawsuit alleges that Inovio made materially false and misleading statements about its business, operations, and prospects, including issues with the manufacturing of its CELLECTRA device and the regulatory timeline for its INO-3107 treatment, which allegedly resulted in investor losses.

Why it matters

This lawsuit highlights the importance of transparency and accurate disclosures from public companies. Investors who suffered losses on Inovio stock during the class period may be able to recover those losses by joining the class action lawsuit against the company.

The details

The lawsuit alleges that Inovio failed to disclose to investors that there were manufacturing issues with its CELLECTRA device, which delayed the expected submission of the INO-3107 Biologics License Application (BLA) to the FDA. The company also allegedly overstated the prospects for INO-3107's regulatory approval and commercialization. As a result of these alleged misrepresentations, Inovio's stock price declined significantly when the issues were disclosed to the public.

  • The class period covers October 10, 2023 to December 26, 2025.
  • Inovio released its Q2 2024 financial results on August 8, 2024, revealing a delay in the INO-3107 BLA submission.
  • On December 29, 2025, Inovio disclosed that the FDA had accepted the INO-3107 BLA on a standard review timeline rather than the accelerated review timeline.

The players

Inovio Pharmaceuticals, Inc.

A biopharmaceutical company that develops DNA medicines to treat and prevent infectious diseases, cancer, and other diseases.

Glancy Prongay Wolke & Rotter LLP

A law firm representing investors in the class action lawsuit against Inovio.

Got photos? Submit your photos here. ›

What’s next

The deadline for investors to file as a lead plaintiff in the class action lawsuit is April 7, 2026.

The takeaway

This lawsuit highlights the importance of accurate and transparent disclosures from public companies. Investors who suffered losses on Inovio stock during the class period may be able to recover those losses by joining the class action lawsuit against the company.